help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nauck, M. A.
Right arrow Articles by Creutzfeldt, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nauck, M. A.
Right arrow Articles by Creutzfeldt, W.

Journal of Clinical Endocrinology & Metabolism, Vol 76, 912-917, Copyright © 1993 by Endocrine Society

ARTICLES

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

MA Nauck, E Bartels, C Orskov, R Ebert and W Creutzfeldt
Department of Medicine, Georg August University, Gottingen, Germany.

Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1-(7-36) amide (GLP-1) are glucose-dependent insulinotropic gut hormones that may explain the greater insulin secretory response with oral compared to i.v. glucose (incretin effect). To study their individual and combined contributions, in eight healthy volunteers, on separate occasions, synthetic human GIP (1 pmol/kg.min) and/or GLP-1 (0.3 pmol/kg.min) or placebo were infused i.v. (-30 to 120 min), while at 0 min, a glucose infusion "isoglycemic" to the profile after an oral glucose load of 50 g/400 mL was started. After the administration of 50 g oral glucose, immunoreactive GIP rose several-fold to 337 +/- 43 pmol/L, while there was only a transient (10-30 min) and moderate increment in immunoreactive GLP-1 (from basal, 25-30, to 41 +/- 4 pmol/L). Isoglycemic i.v. glucose infusions led to smaller B-cell responses (estimated incretin effect, 41 +/- 5%). With single infusions of GIP or GLP-1 (circulating concentrations, 464 +/- 73 and 54 +/- 3 pmol/L, respectively), B-cell responses were significantly augmented compared to i.v. glucose alone and were no longer significantly different from those after oral glucose. The combination of GIP and GLP- 1 led to B-cell responses that were significantly higher than those with either hormone alone (additive mode of cooperation). Plasma GIP concentrations were similar after endogenous secretion (oral glucose) and i.v. infusion, while exogenously administered GLP-1 led to plasma levels that were maintained at an elevated level for a longer period during exogenous infusion than after stimulation by oral glucose. When, in seven volunteers, a lower dose (0.15 pmol/kg.min) of GLP-1 was infused during isoglycemic glucose infusion experiments only for the duration of elevated plasma levels in the oral glucose challenges (0-30 min), a significant, but transient, increment in insulin and C-peptide concentrations was observed, which was equivalent to 26 +/- 10% of the estimated incretin effect. Therefore, in conclusion, circulating GIP seems to make a major contribution to the incretin effect after oral glucose, and GLP-1 appears to mediate a smaller proportion. GIP and GLP- 1 can interact in an additive manner in normal man.


This article has been cited by other articles:


Home page
 Diabetes CareHome page
M. A. Nauck, R. E. Ratner, C. Kapitza, R. Berria, M. Boldrin, and R. Balena
Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study
Diabetes Care, July 1, 2009; 32(7): 1237 - 1243.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Vollmer, H. Gardiwal, B. A. Menge, O. Goetze, C. F. Deacon, W. E. Schmidt, J. J. Holst, and J. J. Meier
Hyperglycemia Acutely Lowers the Postprandial Excursions of Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide in Humans
J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1379 - 1385.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Salehi, T. P. Vahl, and D. A. D'Alessio
Regulation of Islet Hormone Release and Gastric Emptying by Endogenous Glucagon-Like Peptide 1 after Glucose Ingestion
J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4909 - 4916.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S. Huttner, E. U. Graefe-Mody, B. Withopf, A. Ring, and K. A. Dugi
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers
J. Clin. Pharmacol., October 1, 2008; 48(10): 1171 - 1178.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. Vollmer, J. J. Holst, B. Baller, M. Ellrichmann, M. A. Nauck, W. E. Schmidt, and J. J. Meier
Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance
Diabetes, March 1, 2008; 57(3): 678 - 687.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
K. M. S. Johnson, D. S. Edgerton, T. Rodewald, M. Scott, B. Farmer, D. Neal, and A. D. Cherrington
Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization
Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E380 - E384.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
E. T. Parlevliet, A. C. Heijboer, J. P. Schroder-van der Elst, L. M. Havekes, J. A. Romijn, H. Pijl, and E. P. M. Corssmit
Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet
Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E142 - E147.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
J. J. Holst
The Physiology of Glucagon-like Peptide 1
Physiol Rev, October 1, 2007; 87(4): 1409 - 1439.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. P. Vahl, M. Tauchi, T. S. Durler, E. E. Elfers, T. M. Fernandes, R. D. Bitner, K. S. Ellis, S. C. Woods, R. J. Seeley, J. P. Herman, et al.
Glucagon-Like Peptide-1 (GLP-1) Receptors Expressed on Nerve Terminals in the Portal Vein Mediate the Effects of Endogenous GLP-1 on Glucose Tolerance in Rats
Endocrinology, October 1, 2007; 148(10): 4965 - 4973.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
K. M. S. Johnson, D. S. Edgerton, T. Rodewald, M. Scott, B. Farmer, D. Neal, and A. D. Cherrington
Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels
Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E1085 - E1091.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. E. Dunning and J. E. Gerich
The Role of {alpha}-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications
Endocr. Rev., May 1, 2007; 28(3): 253 - 283.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
Y.-L. He, Y. Wang, J. M. Bullock, C. F. Deacon, J. J. Holst, B. E. Dunning, M. Ligueros-Saylan, and J. E. Foley
Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT
J. Clin. Pharmacol., May 1, 2007; 47(5): 633 - 641.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R K. Campbell
Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus
Ann. Pharmacother., January 1, 2007; 41(1): 51 - 60.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
G. E. Lim and P. L. Brubaker
Glucagon-Like Peptide 1 Secretion by the L-Cell: The View From Within
Diabetes, December 1, 2006; 55(Supplement_2): S70 - S77.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
V. Ionut, I. F. Liberty, K. Hucking, M. Lottati, D. Stefanovski, D. Zheng, and R. N. Bergman
Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action
Am J Physiol Endocrinol Metab, October 1, 2006; 291(4): E779 - E785.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
T. J. Little, S. Doran, J. H. Meyer, A. J. P. M. Smout, D. G. O'Donovan, K.-L. Wu, K. L. Jones, J. Wishart, C. K. Rayner, M. Horowitz, et al.
The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed
Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E647 - E655.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. J. Little, A. N. Pilichiewicz, A. Russo, L. Phillips, K. L. Jones, M. A. Nauck, J. Wishart, M. Horowitz, and C. Feinle-Bisset
Effects of Intravenous Glucagon-Like Peptide-1 on Gastric Emptying and Intragastric Distribution in Healthy Subjects: Relationships with Postprandial Glycemic and Insulinemic Responses
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1916 - 1923.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M Horowitz and M A Nauck
To be or not to be--an incretin or enterogastrone?
Gut, February 1, 2006; 55(2): 148 - 150.
[Full Text] [PDF]

Home page
 GutHome page
J Schirra, M Nicolaus, R Roggel, M Katschinski, M Storr, H J Woerle, and B Goke
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
Gut, February 1, 2006; 55(2): 243 - 251.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. J. Meier, G. Kemmeries, J. J. Holst, and M. A. Nauck
Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects
Diabetes, July 1, 2005; 54(7): 2212 - 2218.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Miki, K. Minami, H. Shinozaki, K. Matsumura, A. Saraya, H. Ikeda, Y. Yamada, J. J. Holst, and S. Seino
Distinct Effects of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 on Insulin Secretion and Gut Motility
Diabetes, April 1, 2005; 54(4): 1056 - 1063.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Ferrannini, A. Gastaldelli, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo
{beta}-Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 493 - 500.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. J. Holst and C. Orskov
The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism
Diabetes, December 1, 2004; 53(suppl_3): S197 - S204.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. J. Meier, B. Gallwitz, B. Kask, C. F. Deacon, J. J. Holst, W. E. Schmidt, and M. A. Nauck
Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects
Diabetes, December 1, 2004; 53(suppl_3): S220 - S224.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. J. Holst and J. Gromada
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Am J Physiol Endocrinol Metab, August 1, 2004; 287(2): E199 - E206.
[Abstract] [Full Text] [PDF]

Home page
 JRSMHome page
C M. B Edwards
GLP-1: target for a new class of antidiabetic agents?
J R Soc Med, June 1, 2004; 97(6): 270 - 274.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. J. Meier, O. Goetze, J. Anstipp, D. Hagemann, J. J. Holst, W. E. Schmidt, B. Gallwitz, and M. A. Nauck
Gastric inhibitory polypeptide does not inhibit gastric emptying in humans
Am J Physiol Endocrinol Metab, April 1, 2004; 286(4): E621 - E625.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. A. Hinke, S. Manhart, K. Kuhn-Wache, C. Nian, H.-U. Demuth, R. A. Pederson, and C. H. S. McIntosh
[Ser2]- and [Ser(P)2]Incretin Analogs: COMPARISON OF DIPEPTIDYL PEPTIDASE IV RESISTANCE AND BIOLOGICAL ACTIVITIES IN VITRO AND IN VIVO
J. Biol. Chem., February 6, 2004; 279(6): 3998 - 4006.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
B. Ahren, J. J. Holst, and A. Mari
Characterization of GLP-1 Effects on {beta}-Cell Function After Meal Ingestion in Humans
Diabetes Care, October 1, 2003; 26(10): 2860 - 2864.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Basu, E. Breda, A. L. Oberg, C. C. Powell, C. Dalla Man, A. Basu, J. L. Vittone, G. G. Klee, P. Arora, M. D. Jensen, et al.
Mechanisms of the Age-Associated Deterioration in Glucose Tolerance: Contribution of Alterations in Insulin Secretion, Action, and Clearance
Diabetes, July 1, 2003; 52(7): 1738 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. Quddusi, T. P. Vahl, K. Hanson, R. L. Prigeon, and D. A. D'Alessio
Differential Effects of Acute and Extended Infusions of Glucagon-Like Peptide-1 on First- and Second-Phase Insulin Secretion in Diabetic and Nondiabetic Humans
Diabetes Care, March 1, 2003; 26(3): 791 - 798.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
L. L. Kjems, J. J. Holst, A. Volund, and S. Madsbad
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on {beta}-Cell Sensitivity in Type 2 and Nondiabetic Subjects
Diabetes, February 1, 2003; 52(2): 380 - 386.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. W. Van Citters, M. Kabir, S. P. Kim, S. D. Mittelman, M. K. Dea, P. L. Brubaker, and R. N. Bergman
Elevated Glucagon-Like Peptide-1-(7-36)-Amide, but Not Glucose, Associated with Hyperinsulinemic Compensation for Fat Feeding
J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5191 - 5198.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. J. Greenbaum, R. L. Prigeon, and D. A. D'Alessio
Impaired {beta}-Cell Function, Incretin Effect, and Glucagon Suppression in Patients With Type 1 Diabetes Who Have Normal Fasting Glucose
Diabetes, April 1, 2002; 51(4): 951 - 957.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. A. Nauck, M. M. Heimesaat, K. Behle, J. J. Holst, M. S. Nauck, R. Ritzel, M. Hufner, and W. H. Schmiegel
Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1239 - 1246.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. J. Meier, K. Hucking, J. J. Holst, C. F. Deacon, W. H. Schmiegel, and M. A. Nauck
Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes
Diabetes, November 1, 2001; 50(11): 2497 - 2504.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. A. Reimer, C. Darimont, S. Gremlich, V. Nicolas-Metral, U. T. Ruegg, and K. Mace
A Human Cellular Model for Studying the Regulation of Glucagon-Like Peptide-1 Secretion
Endocrinology, October 1, 2001; 142(10): 4522 - 4528.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Larsen, B. Hylleberg, K. Ng, and P. Damsbo
Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment
Diabetes Care, August 1, 2001; 24(8): 1416 - 1421.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. F. Deacon, P. Danielsen, L. Klarskov, M. Olesen, and J. J. Holst
Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs
Diabetes, July 1, 2001; 50(7): 1588 - 1597.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
F. C. Lynn, N. Pamir, E. H.C. Ng, C. H.S. McIntosh, T. J. Kieffer, and R. A. Pederson
Defective Glucose-Dependent Insulinotropic Polypeptide Receptor Expression in Diabetic Fatty Zucker Rats
Diabetes, May 1, 2001; 50(5): 1004 - 1011.
[Abstract] [Full Text]

Home page
 DiabetesHome page
R. Ritzel, M. Schulte, N. Pørksen, M. S. Nauck, J. J. Holst, C. Juhl, W. März, O. Schmitz, W. H. Schmiegel, and M. A. Nauck
Glucagon-Like Peptide 1 Increases Secretory Burst Mass of Pulsatile Insulin Secretion in Patients With Type 2 Diabetes and Impaired Glucose Tolerance
Diabetes, April 1, 2001; 50(4): 776 - 784.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. A. D’Alessio, T. J. Kieffer, G. J. Taborsky Jr., and P. J. Havel
Activation of the Parasympathetic Nervous System Is Necessary for Normal Meal-Induced Insulin Secretion in Rhesus Macaques
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1253 - 1259.
[Abstract] [Full Text]

Home page
 DiabetesHome page
T. Vilsbøll, T. Krarup, C. F. Deacon, S. Madsbad, and J. J. Holst
Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients
Diabetes, March 1, 2001; 50(3): 609 - 613.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. C. Moore, P.-S. Hsieh, D. W. Neal, and A. D. Cherrington
Nonhepatic response to portal glucose delivery in conscious dogs
Am J Physiol Endocrinol Metab, December 1, 2000; 279(6): E1271 - E1277.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. F. Deacon, M. A. Nauck, J. Meier, K. Hücking, and J. J. Holst
Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide
J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3575 - 3581.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
J. T. Lewis, B. Dayanandan, J. F. Habener, and T. J. Kieffer
Glucose-Dependent Insulinotropic Polypeptide Confers Early Phase Insulin Release to Oral Glucose in Rats: Demonstration by a Receptor Antagonist
Endocrinology, October 1, 2000; 141(10): 3710 - 3716.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J Schirra, P Houck, U Wank, R Arnold, B Goke, and M Katschinski
Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans
Gut, May 1, 2000; 46(5): 622 - 631.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
T. J. Kieffer and J. Francis Habener
The Glucagon-Like Peptides
Endocr. Rev., December 1, 1999; 20(6): 876 - 913.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
E. Naslund, J. Bogefors, S. Skogar, P. Gryback, H. Jacobsson, J. J. Holst, and P. M. Hellstrom
GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 1999; 277(3): R910 - R916.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C.-C. Tseng, X.-Y. Zhang, and M. M. Wolfe
Effect of GIP and GLP-1 antagonists on insulin release in the rat
Am J Physiol Endocrinol Metab, June 1, 1999; 276(6): E1049 - E1054.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
P. L. Brubaker, J. Schloos, and D. J. Drucker
Regulation of Glucagon-Like Peptide-1 Synthesis and Secretion in the GLUTag Enteroendocrine Cell Line
Endocrinology, October 1, 1998; 139(10): 4108 - 4114.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Hovorka, L. Chassin, S. D. Luzio, R. Playle, and D. R. Owens
Pancreatic {beta}-Cell Responsiveness during Meal Tolerance Test: Model Assessment in Normal Subjects and Subjects with Newly Diagnosed Noninsulin-Dependent Diabetes Mellitus
J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 744 - 750.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. A. Nauck, U. Niedereichholz, R. Ettler, J. J. Holst, C. Orskov, R. Ritzel, and W. H. Schmiegel
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
Am J Physiol Endocrinol Metab, November 1, 1997; 273(5): E981 - E988.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. J. Balks, J. J. Holst, A. von zur Muhlen, and G. Brabant
Rapid Oscillations in Plasma Glucagon-Like Peptide-1 (GLP-1) in Humans: Cholinergic Control of GLP-1 Secretion via Muscarinic Receptors
J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 786 - 790.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1993 by The Endocrine Society